Search Results

Bristol Myers Squibb (NYSE: BMY) today announced that its Board of Directors has elected independent director Michael R. McMullen to the Board, effective July 1, 2024.

The FDA’s year-end rush includes nine target action dates, mostly for rare disease and cancer therapies.

Bristol Myers Squibb announced that it recently became aware of an unsolicited “mini-tender” offer by Tutanota LLC to purchase up to five hundred thousand shares of Bristol Myers Squibb’s common stock, representing significantly less than one percent of Bristol Myers Squibb’s common stock outstanding, at an offer price of $55 per share.

Evotec SE announced that the Company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 m to Evotec.